← Leaderboards
Stephen M Tuel
Phase V Pharmaceuticals, Inc.
$941,224
Attributed
$941,224
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $735.6K · FY2005–06$1M$750K$500K$250K$0
'05
'06
Funding mix
By agency
NIH$941,224 · 2
By mechanism
R44$941,224 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /Production
Grant awards (4)
Baclofen formulation for spasticity with dysphagia$105,652
R44 · FY2006 · HD · contact PI
Tizanidine formulation for spasticity with dysphagia$100,000
R44 · FY2006 · HD · contact PI
Baclofen formulation for spasticity with dysphagia$635,572
R44 · FY2005 · HD
Baclofen formulation for spasticity with dysphagia$100,000
R44 · FY2005 · HD